1. Do European populations differ with respect to frequency of the phenotype slow debrisoquine oxidation?;Alván;Eur. J. clin. Pharmac.,1990
2. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer;Ayesh;Nature,1984
3. Boobis , A. R. Speirs , C. J. Murray , S. Davies , D. S. 1987 Potency and reversibility of quinidine inhibition of debrisoquine 4-hydroxylase activity in man Abstr. Xth International Congress of Pharmacology, Sydney, Australia
4. The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al. 1990);Caporaso;Br. J. clin. Pharmac.,1990
5. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype;Caporaso;Cancer Res.,1989a